Clinicopathologic Syndromes of Viral Hepatitis

Slide 1 · Clinicopathologic Syndromes

of Viral Hepatitis

Clinical patterns • injury mechanisms • morphology • interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish the five clinical syndromes of hepatotropic viral infection.

Relate acute hepatitis to lobular inflammation, hepatocyte death, and necrosis patterns.

Identify chronic hepatitis by portal inflammation, interface activity, and fibrosis.

Interpret viral markers, biopsy findings, and common diagnostic mimics.

Slide 3 · One infection — several clinicopathologic outcomes

Hepatotropic viral infection

Acute infection

Recovery or persistence

Acute infection can be asymptomatic, symptomatic, or complicated by liver failure.

Persistent infection may present as chronic hepatitis or an asymptomatic reservoir.

Schematic

Slide 4 · Histology alone cannot identify the virus

Hepatitis viruses produce overlapping patterns of hepatocellular injury.

Autoimmune hepatitis, drug-induced injury, and Wilson disease may resemble viral hepatitis.

Serologic and molecular tests determine the viral etiology.

Morphology identifies the injury pattern; Virologic testing identifies the agent.

Slide 5 · Transmission and persistence: Broad viral differences

Virus

Principal transmission

Chronic infection pattern

HAV

Fecal–oral

Does not cause chronic infection

HBV

Parenteral / sexual / perinatal

Chronic infection can develop

HCV

Primarily parenteral

Frequently persists

HDV

Parenteral with HBV

HBV required for infection

HEV

Fecal–oral

Persistence mainly in immunocompromised hosts

Summary based on the viral chapters and Table 18.3.

Slide 6 · Acute infection: Symptomatic versus asymptomatic

Asymptomatic

Few or no clinically recognized symptoms

Recognized by elevated aminotransferases

Antibodies may establish previous infection

Symptomatic

Clinically apparent hepatitis develops

Clinical course has four named phases

May resolve or progress to liver failure

Slide 7 · Asymptomatic infection with recovery

Infection can be clinically silent despite hepatocellular injury.

Aminotransferases may be only minimally elevated.

Prior infection may be recognized retrospectively by antiviral antibodies.

Absence of jaundice or symptoms does not exclude prior viral hepatitis.

Slide 8 · Serologic evidence after silent infection

Anti-HAV antibodies can document previous HAV exposure.

Anti-HBV antibodies may identify a prior subclinical HBV infection.

Interpret antibody type and accompanying markers before assigning infection status.

Slide 9 · Symptomatic acute hepatitis: Four clinical phases

Incubation

Preicteric symptoms

Icteric phase

Convalescence

These phases describe the typical symptomatic sequence; Individual infections vary.

The presence or absence of jaundice does not identify the virus.

Schematic

Slide 10 · Incubation is clinically silent but not inert

Incubation precedes recognized symptoms.

Different viruses have different incubation intervals.

Virus transmission can occur before the patient becomes visibly ill.

Slide 11 · Incubation intervals summary

Virus

Typical incubation interval

Clinical implication

HAV

2–6 weeks

Exposure may precede symptoms by weeks

HBV

2–26 weeks

Broad interval between exposure and illness

HCV

4–26 weeks

Most acute infections are subclinical

HDV

Similar to HBV

Requires simultaneous or preceding HBV

HEV

About 4–5 weeks

Fecal–oral exposure precedes illness

Intervals reflect Robbins Table 18.3; Avoid using them as diagnostic cutoffs.

Slide 12 · Preicteric symptoms precede jaundice

The preicteric phase represents symptomatic illness before visible jaundice.

A clinical syndrome may be recognized before overt bilirubin-related findings.

Clinical findings alone cannot reliably distinguish HAV, HBV, HCV, HDV, and HEV.

Slide 13 · Icteric hepatitis is a clinical phenotype

Jaundice defines the icteric phase of symptomatic acute hepatitis.

Its timing follows the incubation and preicteric phases.

The severity of symptoms must be evaluated separately from virologic identity.

Slide 14 · Convalescence and recovery

The convalescent phase follows acute symptoms.

Recovery may be established clinically and by appropriate virologic follow-up.

The distinction between viral clearance and persistence depends on the specific infection.

Slide 15 · When is acute hepatitis most infectious?

Late incubation

Early symptoms

Later acute illness

Peak infectivity near the end of the asymptomatic incubation period and early acute symptoms.

Practical implication: Symptom-based case recognition may occur after transmission has begun.

Schematic

Slide 16 · Typical clinical trajectories vary by virus

HAV and HEV

Acute infections dominate in immunocompetent hosts

HAV does not cause chronic hepatitis

HEV can be severe during pregnancy

HBV, HCV and HDV

HBV can recover or persist

HCV commonly progresses to persistence

HDV modifies the course of underlying HBV

Slide 17 · Acute liver failure is an exceptional severe outcome

A minority of hepatotropic viral infections lead to acute liver failure.

The morphologic substrate may be widespread or massive hepatocyte necrosis.

Clinical deterioration reflects loss of viable functioning liver parenchyma.

Slide 18 · Viruses implicated in acute liver failure

The textbook attributes a subset of acute liver failure cases to viral hepatitis.

HAV and HEV are prominent worldwide causes of viral-associated acute failure.

The relative contribution of HBV varies geographically.

Slide 19 · HEV in pregnancy: Clinically important vulnerability

HEV usually causes self-limited acute hepatitis in immunocompetent hosts.

Pregnancy is associated with an increased risk of severe HEV-associated hepatitis.

Severe cases may progress to liver failure.

Slide 20 · Acute failure: Tissue loss versus recovery

Extensive necrosis

Residual viable hepatocytes

Regeneration / recovery

Supportive care maintains the patient while surviving hepatocytes regenerate.

Failure to recover in time can necessitate liver transplantation.

Schematic

Slide 21 · Acute hepatitis: Gross liver appearances

Uncomplicated or inflamed liver

May remain normal in size

Can become enlarged from inflammation

Gross appearance is not pathogen-specific

Severe liver failure

May become reduced in size

Extensive necrosis explains tissue collapse

Functional failure tracks the loss of viable hepatocytes

Slide 22 · Acute hepatitis: Lobular-predominant injury

Portal tract

Central vein

Lobular injury + lymphocytes

Original conceptual schematic — not a histologic specimen

Interpretation

Inflammatory cells involve portal areas and lobules.

Hepatocytes show injury, apoptosis, and necrosis.

Pigmented macrophages scavenge cellular debris.

Slide 23 · The acute inflammatory infiltrate

Lymphocytes predominate in both portal and lobular compartments.

Variable plasma cells and eosinophils may also appear.

Inflammation by itself does not distinguish viral from autoimmune or drug-related hepatitis.

Slide 24 · Portal and lobular compartments in acute hepatitis

Portal compartment

Inflammation may occupy the portal tract

Not necessarily accompanied by established fibrosis

May coexist with lobular hepatocyte injury

Lobular compartment

Inflammatory cells intermix with hepatocytes

Apoptosis and necrosis can occur

Pigmented macrophages may be scattered in injured zones

Slide 25 · Apoptosis: Single-cell hepatocyte loss

Viral-associated hepatocellular damage may induce apoptosis.

An apoptotic hepatocyte represents death of an individual injured cell.

Macrophages remove dead-cell debris from the lobule.

Slide 26 · Necrosis: Hepatocyte death can be confluent

Necrosis may affect clusters rather than isolated hepatocytes.

Confluent necrosis denotes loss of groups of adjacent hepatocytes.

Increasing continuity and extent of necrosis indicate more severe injury.

Slide 27 · Pigmented macrophages follow cell loss

Macrophages phagocytose material released from dead hepatocytes.

Pigment-containing macrophages can therefore mark prior or ongoing cell injury.

This reaction accompanies but does not identify the cause of hepatitis.

Slide 28 · Increasing extent of hepatocyte necrosis

Single-cell injury

Confluent necrosis

Bridging / panlobular necrosis

Necrosis that forms bridges links vascular regions of the lobule.

Panlobular necrosis involves an entire lobule; Massive necrosis may produce liver failure.

Schematic

Slide 29 · Bridging necrosis links vascular structures

Confluent hepatocyte necrosis links vascular regions

Original conceptual schematic — not a histologic specimen

Interpretation

The term describes continuity of necrotic zones.

The bridge may connect portal and/or central vascular regions.

It is a severity pattern, not a virus-specific lesion.

Slide 30 · Panlobular necrosis reflects extensive injury

Panlobular or panacinar necrosis involves the whole functional lobular unit.

It can develop when necrosis spreads beyond small isolated groups.

Widespread necrosis threatens hepatic functional reserve.

Slide 31 · Confluent versus bridging versus massive necrosis

Confluent / bridging

Confluent: Groups of hepatocytes die together

Bridging: Confluent necrosis connects vascular regions

Severity is assessed by extent and distribution

Massive liver necrosis

Very large areas of parenchyma are lost

May lead to shrunken liver and liver failure

Recovery requires sufficient remaining hepatocytes

Slide 32 · Acute hepatitis may include cholestasis

Cholestasis can accompany lobular hepatocellular injury.

The textbook schematic includes cholestasis among acute injury findings.

Interpret cholestasis alongside inflammation, cell injury, and the clinical presentation.

Slide 33 · What acute histology can and cannot establish

Can describe

Portal and lobular inflammation

Apoptosis, necrosis, and necrosis distribution

Presence of cholestatic change

Cannot reliably establish

Whether the culprit is HAV, HBV, HCV, HDV, or HEV

Whether a similar pattern is drug-induced

Whether autoimmunity or Wilson disease is the cause

Slide 34 · Etiologic investigation uses serology and nucleic acids

Virus

Serologic testing highlighted by Robbins

Molecular method

HAV

Anti-HAV IgM

—

HBV

HBsAg / anti-HBc

HBV DNA PCR

HCV

Anti-HCV antibody

HCV RNA PCR

HDV

Anti-HDV IgM or IgG

HDV RNA PCR

HEV

Anti-HEV IgM or IgG

HEV RNA PCR

Marker combinations and timing require clinical interpretation.

Slide 35 · The key diagnostic distinction in a hepatitis pattern

Hepatitic injury pattern

Serology / viral RNA or DNA

Etiologic attribution

Morphology assesses the tissue response and injury severity.

Serologic and molecular testing provides evidence of the causative virus.

Schematic

Slide 36 · Acute infection may progress to persistence

HBV and particularly HCV account for much of chronic viral hepatitis.

Progression is not universal and differs by virus and host setting.

The chronic syndrome may have minimal symptoms despite ongoing disease.

Slide 37 · Chronic hepatitis: Operational clinicopathologic definition

The textbook defines continuing or relapsing hepatic disease beyond six months.

Clinical, biochemical, or serologic evidence may indicate chronicity.

Morphologic fibrosis can support a chronic disease process.

Histology and longitudinal clinical evidence are complementary, not interchangeable.

Slide 38 · Chronic hepatitis can remain clinically silent

Persistent aminotransferase elevation may be the only recognized finding.

Absence of symptoms does not exclude ongoing inflammation and fibrosis.

The degree of clinical disturbance need not mirror histologic injury.

Slide 39 · Symptoms of chronic viral hepatitis

Fatigue is the most common symptom described in the source.

Malaise and loss of appetite may occur.

Occasional episodes of mild jaundice can accompany chronic disease.

Slide 40 · Laboratory features in chronic hepatitis

Aminotransferases may remain persistently elevated.

Prothrombin time prolongation and hyperglobulinemia may occur.

Hyperbilirubinemia or mild alkaline phosphatase elevations can also appear.

Slide 41 · Immune complexes produce extrahepatic disease

Persistent antigen

Antibody binding

Circulating complexes

Vasculitis

Glomerulonephritis

Cryoglobulinemia

Extrahepatic immune-complex disease

Original conceptual schematic — not a histologic specimen

Interpretation

Chronic HBV or HCV can generate antigen–antibody complexes.

Extrahepatic disease may involve vessels, kidney, or circulating cryoglobulins.

Extrahepatic manifestations do not replace virologic testing.

Slide 42 · Vasculitis as an extrahepatic manifestation

Circulating antigen–antibody complexes may produce vascular inflammation.

Vasculitis can therefore accompany chronic HBV or HCV infection.

A vascular manifestation does not automatically establish viral etiology.

Slide 43 · Glomerulonephritis in chronic viral hepatitis

Immune-complex disease may involve renal glomeruli.

Renal manifestations can be part of systemic HBV/HCV-associated disease.

Interpret renal disease within the broader infectious and clinical context.

Slide 44 · Cryoglobulinemia provides another systemic clue

Cryoglobulinemia is included among immune-complex syndromes in chronic HBV/HCV.

It reflects extrahepatic immune phenomena during ongoing infection.

The liver and systemic manifestations may require parallel evaluation.

Slide 45 · Chronic hepatitis: Portal inflammation and interface injury

Portal infiltrate

Interface injury

Portal boundary

Original conceptual schematic — not a histologic specimen

Interpretation

Portal lymphocytes / plasma cells expand portal tracts.

Inflammatory cells cross the limiting plate.

Periportal hepatocyte damage constitutes interface activity.

Slide 46 · Portal infiltrates define the chronic pattern

The characteristic chronic hepatitis infiltrate is portal and lymphocytic.

Lymphoplasmacytic inflammation is another common description.

Fibrosis accompanies the characteristic chronic histologic pattern.

Slide 47 · Interface activity indicates active periportal injury

Inflammation extends across the portal limiting plate.

Adjacent periportal hepatocytes are damaged.

Interface activity reflects inflammatory injury rather than fibrosis stage alone.

Slide 48 · Portal inflammation versus interface activity

Portal inflammation

Inflammatory cells occupy portal stroma

May expand the portal tract

Important component of chronic hepatitis

Interface activity

Cells breach the portal–parenchymal boundary

Periportal hepatocytes are injured

An indicator of inflammatory activity

Slide 49 · Lobular activity may persist in chronic disease

Chronic hepatitis often has superimposed lobular inflammation.

The amount of lobular injury is variable.

Portal and lobular components should be assessed separately.

Slide 50 · Fibrosis begins around the portal tract

Portal fibrosis is an early structural consequence of chronic injury.

Periportal fibrosis reflects extension beyond the portal compartment.

Fibrosis may increase as chronic hepatocyte damage continues.

Slide 51 · Portoportal bridging fibrosis marks progression

Fibrous connections develop between portal tracts.

Bridging fibrosis indicates more advanced architectural remodeling.

Bridging fibrosis is different from bridging necrosis.

Slide 52 · Chronic liver injury: Sequence of fibrosis

Portal

Periportal

Bridging

Cirrhosis

Portal scar expands → bridges → nodular remodeling

Original conceptual schematic — not a histologic specimen

Interpretation

Initial portal / periportal fibrous tissue.

Bridges eventually connect portal regions.

Advanced remodeling culminates in cirrhosis.

Slide 53 · Cirrhosis is the architectural endpoint

Continuing chronic hepatitis can culminate in cirrhosis.

Cirrhosis reflects advanced distortion of hepatic architecture by fibrosis.

Chronic HBV/HCV also increase hepatocellular carcinoma risk.

Slide 54 · Inflammatory grade and fibrosis stage

Grade: Activity

Describes degree of inflammation / ongoing injury

Includes interface and lobular inflammatory activity

May change as inflammatory activity changes

Stage: Fibrosis

Describes amount and distribution of scar tissue

Progresses from portal fibrosis to bridging and cirrhosis

Helps guide clinical management

Slide 55 · Why obtain a liver biopsy?

Histology may support a diagnosis of chronic hepatitis.

Biopsy can assess inflammatory activity (grade).

Biopsy can assess fibrosis (stage) that informs management with clinical parameters.

Slide 56 · Biopsy does not replace etiologic testing

Acute and chronic viral hepatitis overlap with autoimmune injury.

Drug reactions and Wilson disease can generate similar inflammatory patterns.

Serologic and molecular testing remains crucial to assign viral etiology.

Slide 57 · HBV: Ground-glass hepatocyte is an antigen effect

Accumulated HBsAg in endoplasmic reticulum

Original conceptual schematic — not a histologic specimen

Interpretation

Endoplasmic reticulum contains accumulated HBsAg.

Cytoplasm develops a finely granular, ground-glass appearance.

HBsAg immunostaining can verify antigen accumulation.

Slide 58 · Ground-glass change and HBV infection

The ground-glass hepatocyte is characteristic of chronic HBV.

The cytoplasmic appearance reflects retained HBsAg in endoplasmic reticulum.

Morphology suggests HBV; Antigen-specific staining provides confirmation.

Slide 59 · HBV immunohistochemistry: Complementary antigens

HBsAg staining identifies hepatitis B surface antigen in tissue.

HBcAg staining can provide additional viral antigen evidence.

Viral antigen localization complements serologic and molecular tests.

Slide 60 · HCV: Portal lymphoid aggregates

Lymphoid aggregate

Adjacent liver parenchyma

Original conceptual schematic — not a histologic specimen

Interpretation

Chronic HCV often produces conspicuous portal lymphoid aggregates.

Some aggregates organize into lymphoid follicles.

The pattern is characteristic but not independently diagnostic.

Slide 61 · HCV-associated steatosis

Fat accumulation is common in chronic HCV infection.

Steatosis can be especially pronounced with HCV genotype 3.

Steatosis is a morphologic clue, not proof of HCV infection.

Slide 62 · Focal bile duct injury can accompany HCV

Chronic HCV sometimes causes bile duct injury.

The finding may simulate a primary biliary disorder.

description, bile duct injury is typically focal.

Slide 63 · Characteristic morphologic clues: HBV versus HCV

Chronic HBV

Ground-glass hepatocytes

HBsAg accumulates in hepatocyte endoplasmic reticulum

HBsAg / HBcAg immunostains may demonstrate viral antigens

Chronic HCV

Portal lymphoid aggregates or follicles

Steatosis may be prominent, especially genotype 3

Focal bile duct injury may occur

Slide 64 · Carrier state describes transmission without symptoms

A carrier harbors an organism and can transmit it.

Some carriers have no detectable liver disease.

Others have asymptomatic, nonprogressive liver damage.

Slide 65 · The inactive HBV carrier phenotype

Historically called a “healthy carrier” phenotype.

HBsAg and anti-HBe present; HBeAg absent.

Normal aminotransferases, low or undetectable HBV DNA, and little significant hepatic injury.

“Healthy carrier” is historical terminology; Do not infer absence of transmission risk.

Slide 66 · Do not equate HBV and HCV carrier categories

HBV

A low-replication, asymptomatic carrier phenotype is described

Virus may still be present and transmissible

Requires biochemical and virologic characterization

HCV

No equivalent “healthy carrier” state is recognized

Asymptomatic persistence does not imply a benign inactive-carrier category

Viral RNA testing informs infection status

Slide 67 · HIV changes the course of HBV and HCV

HIV co-infection is an important comorbidity in chronic viral hepatitis.

Untreated HIV increases severity of HBV- or HCV-associated liver disease.

The immunologic setting must be considered when assessing progression.

Slide 68 · Chronic HBV and HCV increase HCC risk

Chronic HBV and HCV are associated with hepatocellular carcinoma.

Risk is especially important in patients who develop cirrhosis.

The histologic trajectory links persistent injury, fibrosis, and late consequences.

Slide 69 · From viral infection to progressive liver disease

Persistent infection

Portal/interface injury

Fibrosis → cirrhosis

HCC risk

This is a possible disease trajectory, not an inevitable outcome for every infected person.

Serial clinical, virologic, and fibrosis assessment distinguish patients along this spectrum.

Schematic

Slide 70 · Applied case: Clinically silent infection

A person has no jaundice or apparent systemic illness. Serum transaminases are mildly elevated, and later antiviral antibodies establish prior exposure.

Discuss

Which clinicopathologic syndrome best fits?

Can the causative virus be diagnosed from the absence of symptoms?

Slide 71 · Applied case: Severe acute injury

A patient with clinically acute hepatitis develops liver failure. The liver is reduced in size, with extensive confluent and panlobular hepatocyte necrosis.

Discuss

Which morphologic pattern explains the failure?

Why might the remaining hepatocyte mass determine recovery?

Slide 72 · Applied case: Chronic viral hepatitis

A biopsy shows portal lymphoplasmacytic inflammation, interface activity, and portoportal bridges of fibrous tissue.

Discuss

Which features show inflammatory activity?

Which finding indicates advanced fibrosis stage?

Slide 73 · Applied case: Characteristic viral clues

A biopsy shows portal lymphoid follicles, steatosis, and focal bile duct injury in a patient with evidence of chronic hepatitis.

Discuss

Which virus has this constellation in the Robbins description?

Why are viral serology and RNA testing still necessary?

Slide 74 · Synthesis: Three diagnostic axes

Clinical syndrome: Silent, symptomatic, fulminant, chronic, or carrier state.

Etiology: Virus-specific serology and molecular tests.

Morphology: Injury pattern, inflammatory activity, and fibrosis stage.

A complete diagnosis integrates all three rather than substituting one for another.

Slide 75 · References and source boundaries

Primary: Robbins, Cotran & Kumar, Pathologic Basis of Disease, 11th ed. (2026), Chapter 18.

Core topic: “Clinicopathologic Syndromes of Viral Hepatitis,” printed pp. 760–762.

Virus context: preceding HAV–HEV sections, printed pp. 756–760.

All conceptual diagrams in this lecture are original schematics; no photomicrographs were reproduced.